XML 64 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1

Segments (Tables)

12 Months Ended

Dec. 31, 2018

Summary of Segment Profit

a. Segment information:

		North America				Europe				International Markets
		Year ended December 31,
		2018
		(U.S. $ in millions)
Revenues		$	9,297			$	5,186			$	3,005
Gross profit			4,979				2,884				1,254
R&D expenses			713				283				96
S&M expenses			1,154				1,003				518
G&A expenses			484				325				153
Other income (loss)			(209	)			—				(11	)
Segment profit		$	2,837			$	1,273			$	498

		North America				Europe				International Markets
		Year ended December 31,
		2017
		(U.S. $ in millions)
Revenues		$	12,141			$	5,466			$	3,395
Gross profit			7,322				2,887				1,433
R&D expenses			969				390				154
S&M expenses			1,288				1,130				672
G&A expenses			533				354				189
Other income (loss)			(92	)			(16	)			(8	)
Segment profit		$	4,624			$	1,029			$	426

		North America				Europe				International Markets
		Year ended December 31,
		2016
		(U.S. $ in millions)
Revenues		$	11,778			$	4,969			$	4,015
Gross profit			8,404				2,685				1,811
R&D expenses			1,040				383				205
S&M expenses			1,362				1,267				754
G&A expenses			496				377				226
Other income (loss)			(30	)			(9	)			(10	)
Segment profit		$	5,536			$	667			$	636

Schedule Of Consolidated Income Before Income Tax

		Year ended December 31,
		2018				2017				2016
		(U.S.$ in millions)
North America profit		$	2,837			$	4,624			$	5,536
Europe profit			1,273				1,029				667
International Markets profit			498				426				636
Total segment profit			4,608				6,079				6,839
Profit (loss) of other activities			115				(6	)			8
			4,723				6,073				6,847
Amounts not allocated to segments:
Amortization			1,166				1,444				993
Other asset impairments, restructuring and other items			987				1,836				830
Goodwill impairment			3,027				17,100				900
Intangible asset impairments			1,991				3,238				589
Gain on divestitures, net of divestitures related costs			(66	)			(1,083	)			(720	)
Inventory step-up			—				67				383
Other R&D expenses			83				221				426
Costs related to regulatory actions taken in facilities			14				47				153
Legal settlements and loss contingencies			(1,208	)			500				899
Other unallocated amounts			366				187				240
Consolidated operating income (loss)			(1,637	)			(17,484	)			2,154
Financial expenses, net			959				895				1,330
Consolidated income (loss) before income taxes		$	(2,596	)		$	(18,379	)		$	824

Schedule of Net Sales by Product Line

b. Segment revenues by major products and activities:

The following tables present revenues by major products and activities for each segment for the year ended December 31, 2018, 2017 and 2016:

North America segment:

		Year ended December 31,
		2018				2017				2016
		(U.S.$ in millions)
Generic products		$	4,056			$	5,203			$	4,654
COPAXONE			1,759				3,116				3,543
BENDEKA / TREANDA			642				656				661
ProAir			397				501				565
QVAR			182				313				409
AUSTEDO			204				24				—
Anda			1,347				1,153				301

The table above does not include revenues from other products and activities amounting to $710 million, $1,175 million and $1,645 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Europe segment:

		Year ended December 31,
		2018				2017				2016
		(U.S.$ in millions)
Generic products		$	3,593			$	3,471			$	3,155
COPAXONE			535				595				585
Respiratory products			402				368				239

The table above does not include revenues from other products and activities amounting to $656 million, $1,032 million and $990 million for the years 2018, 2017 and 2016, respectively.

International Markets segment:

		Year ended December 31,
		2018				2017				2016
		(U.S.$ in millions)
Generic products		$	2,022			$	2,370			$	3,129
COPAXONE			72				91				95
Distribution			602				550				458

The table above does not include revenues from other products and activities amounting to $309 million, $384 million and $333 million for the years 2018, 2017 and 2016, respectively.

Schedule of Sales Percentage by Therapeutic Category

The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2018, 2017 and 2016.

		Percentage of Third Party Net Sales
		2018				2017				2016
McKesson Corporation			12	%			16	%			15	%
AmerisourceBergen Corporation			14	%			15	%			19	%

Schedule of Property, Plant and Equipment by Geographic Location

d. Property, plant and equipment—by geographical location were as follows:

		December 31,
		2018				2017
		(U.S. $ in millions)
Israel		$	1,987			$	2,180
United States			950				1,109
Croatia			538				561
Germany			518				423
Czech republic			352				347
Hungary			343				368
Japan			188				376
Other			1,992				2,309
Total property, plant and equipment		$	6,868			$	7,673

X

- Definition

A schedule indicating where long-lived tangible assets are located.

+ References

No definition available.

+ Details

Name:	teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

A schedule of net sales by therapeutic category, stated as a percentage of total sales.

+ References

No definition available.

+ Details

Name:	teva_SalesPercentageByTherapeuticCategoryTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration